Jan Kuiper's Outputs (4)

POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS (2025)
Journal Article
Makos, A., Grime, H., Amarasena, R., Kuiper, J., & Kehoe, O. (in press). POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases, 83, 710-711. https://doi.org/10.1136/annrheumdis-2024-eular.2980

Background:
Psoriatic Arthritis (PsA) is a complex immune-mediated disease. TNF inhibitors (TNFi) are the first-line biologic drugs to treat PsA, targeting soluble TNF-α (sTNF) and membrane-bound TNF-α (mTNF). TNF... Read More about POS0992 PARIS STUDY: POTENTIAL BIOMARKERS PREDICTING RESPONSE TO TNFI IN PSORIATIC ARTHRITIS.

A Randomized Controlled Trial Comparing “Early” Versus “Late” Periosteal Patch Attachment to Knee Chondral Defects in Autologous Chondrocyte Implantation (2024)
Journal Article
Orfanos, G., McCarthy, H. S., Williams, M., Dugard, N., Gallacher, P. D., Glover, A. W., …Kuiper, J. H. (2024). A Randomized Controlled Trial Comparing “Early” Versus “Late” Periosteal Patch Attachment to Knee Chondral Defects in Autologous Chondrocyte Implantation. Cartilage, https://doi.org/10.1177/19476035241279943

Objective
Traditional autologous chondrocyte implantation (ACI) involves arthroscopically harvesting a cartilage biopsy (stage 1), followed by arthrotomy 3-4 weeks later to apply a periosteal patch and implant culture-expanded chondrocytes underneat... Read More about A Randomized Controlled Trial Comparing “Early” Versus “Late” Periosteal Patch Attachment to Knee Chondral Defects in Autologous Chondrocyte Implantation.

125P A review of the management and outcomes of children with SMA in the West Midlands, UK during 2017-2022 (2024)
Journal Article
Willis, T., Kulshrestha, R., Alhaswani, Z., Parasuraman, D., Kuiper, J., Jones, J., & Perry, C. (2024). 125P A review of the management and outcomes of children with SMA in the West Midlands, UK during 2017-2022. Neuromuscular Disorders, 43, Article 104441.23. https://doi.org/10.1016/j.nmd.2024.07.032

169 AGGRECANASE-1 ACTIVITY IN THE SYNOVIAL FLUID OF CARTILAGE INJURY CELL THERAPY TRIAL COHORT PREDICTS OUTCOME 1-YEAR POST TREATMENT. (2024)
Presentation / Conference
Rix, L., Hulme, C. H., Kuiper, J. H., Mennan, C., Gallacher, P., Jermin, P., & Wright, K. T. (2024, January). 169 AGGRECANASE-1 ACTIVITY IN THE SYNOVIAL FLUID OF CARTILAGE INJURY CELL THERAPY TRIAL COHORT PREDICTS OUTCOME 1-YEAR POST TREATMENT. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria